Montek (Sodium Molybdate (99mo))

Sodium molybdate, the active ingredient in Montek, is a chemical compound presented as an injectable solution for intravenous and ocular use. It is employed in clinical and research settings where molybdenum supplementation or diagnostic applications are required and may be utilized under medical supervision.

GNH USA supplies Montek as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Montek (sodium molybdate) is primarily utilized in specialized clinical contexts related to molybdenum metabolism and diagnostic procedures.

- Molybdenum deficiency assessment: aids in evaluating trace element status in patients. - Radiopharmaceutical preparation: serves as a carrier in certain imaging agents. - Ocular surgery adjunct: used experimentally to support wound healing.

Adverse reactions may occur following intravenous or ocular administration of sodium molybdate.

Common Side Effects: - Injection site pain: mild discomfort at the site of IV infusion. - Erythema: localized redness. - Ocular irritation: transient burning or tearing. - Headache: mild to moderate. - Nausea: occasional gastrointestinal upset. - Dizziness: brief sensation of light‑headedness.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe hypersensitivity: rash, swelling, or bronchospasm. - Serum uric acid elevation: potential gout flare. - Renal impairment: decreased kidney function. - Thrombophlebitis: inflammation of veins at infusion site. - Vision changes: unexpected loss of visual acuity.

When using Montek, clinicians should observe standard safety measures and patient‑specific considerations.

- Assess renal function: evaluate baseline kidney status before IV administration. - Monitor for hypersensitivity: watch for rash, pruritus or respiratory difficulty. - Check trace element levels: avoid excess molybdenum accumulation. - Avoid concomitant high‑dose copper supplements: copper may antagonize molybdenum absorption. - Pregnancy and lactation: use only if clearly indicated after risk‑benefit assessment. - Store at ambient temperature: keep in original container, protect from moisture and light.

Sodium molybdate may interact with other agents that affect trace element balance or coagulation pathways.

Major Interactions (Avoid): - Copper supplements: can reduce molybdenum absorption and efficacy. - Anticoagulants: potential additive bleeding risk with intravenous infusion. - High‑dose vitamin B12: theoretical competition for cellular uptake.

Moderate Interactions (Monitor Closely): - Renally excreted drugs: monitor renal function when co‑administered. - Other trace element therapies: adjust dosing to maintain appropriate mineral balance. - Contrast agents: observe for additive nephrotoxicity, especially in patients with compromised kidneys.